UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
AMENDMENT NO. 2
TO
SCHEDULE 13E-3
RULE 13E-3 TRANSACTION STATEMENT UNDER
SECTION 13(E) OF THE
SECURITIES EXCHANGE ACT OF 1934
GENENCOR
INTERNATIONAL, INC.
(Name of the
Issuer)
GENENCOR
INTERNATIONAL, INC.
(Name of Person(s)
Filing Statement)
Common Stock, par
value $0.01 per share
(Title of Class of Securities)
368709 10 1
(CUSIP Number of Class of Securities)
Jean-Jacques Bienaimé
Genencor
International, Inc.
925 Page Mill Road
Palo Alto, CA
94304
(650) 846-7500
(Name, Address and Telephone Number of
Person Authorized to Receive Notices and
Communications on Behalf
of the Person(s) Filing Statement)
With a Copy to:
Keith A. Flaum, Esq.
Cooley Godward LLP
5
Palo Alto Square
3000 El Camino Real
Palo Alto, CA
94306-2155
(650) 843-5000
This statement is filed in
connection with (check the appropriate box):
|
|
a. |
The filing of
solicitation materials or an information statement subject to
Regulation 14A, Regulation 14C or Rule 13e-3(c) under the Securities
Exchange Act of 1934. |
|
|
b. |
The filing of a
registration statement under the Securities Act of 1933. |
Check the following box if the
soliciting materials or information statement referred to in checking
box (a) are preliminary copies:
Calculation of
Filing
Fee
|
|
|
|
|
|
|
Transaction |
|
Amount
of filing fee (2) |
Valuation (1)
$676,053,224 |
|
$79,572 |
|
|
|
(1) |
For
purposes of calculating fee only. This amount is based upon the
purchase of 35,119,648 shares of Common Stock, par value $0.01 per
share, of Genencor International, Inc., at a purchase price of $19.25
per share net in cash. |
|
|
(2) |
Securities Exchange Act of 1934, as
amended, and Fee Rate Advisory No. 6 issued by the Securities and
Exchange Commission on December 9, 2004, is based on a fee rate of
$117.70 per million dollars of the Transaction Valuation. |
|
|
|
Check box if any part of the
fee is offset as provided by Rule 0-11(a)(2) and identify the filing
with which the offsetting fee was previously paid. Identify the
previous filing by registration statement number, or the Form or
Schedule and the date of its filing. |
Amount Previously
Paid: $79,572
Form or Registration No.: Schedule
TO
Filing Party: Danisco A/S, Danisco Holding USA Inc., DH
Subsidiary Inc. and A/S PSE 38 nr. 2024
Date
Filed: February 15,
2005
This Amendment
No. 2 amends and supplements the Schedule 13E-3 initially
filed with the Securities and Exchange Commission on February 15, 2005
as amended by Amendment No. 1 on February 16, 2005 (the
"Schedule 13E-3"), relating to the
tender offer by DH Subsidiary Inc. ("Acquisition
Sub"), a Delaware corporation and an indirect wholly-owned
subsidiary of Danisco A/S, a Danish corporation
("Danisco"), to purchase all of the
outstanding shares of Genencor common stock, $0.01 par value per share
(the "Shares") not owned by Danisco and its
subsidiaries, for a purchase price of $19.25 per Share, net to each
selling stockholder in cash, without interest thereon, upon the terms
and subject to the conditions set forth in Danisco's Offer to
Purchase dated February 15, 2005 (the "Offer to
Purchase"), a copy of which was filed as Exhibit (a)(1)(i)
to the Schedule 13E-3, and in the related Letter of Transmittal (the
"Letter of Transmittal" which, together with
the Offer to Purchase, as amended or supplemented from time to time,
constitute the "Offer"), a copy of which was
filed as Exhibit (a)(1)(ii) to the Schedule 13E-3. On February 15,
2005, Danisco, Acquisition Sub, Danisco Holding USA Inc. and A/S nr.
2024 filed a Tender Offer Statement on Schedule TO (the
"Schedule TO") relating to the Offer.
This Amendment No. 2 is being made to file Exhibit (a)(5)(ix) and to
make certain technical corrections to the Exhibit Index. Item 16 of the
Schedule 13E-3 is amended and restated as set forth below:
|
|
Item 16. |
Exhibits. |
|
|
(a)(1)(i) |
Offer to Purchase, dated
February 15, 2005 (incorporated by reference to Exhibit (a)(1)(i) of
the Schedule TO). |
|
|
(a)(1)(ii) |
Letter of
Transmittal (incorporated by reference to Exhibit (a)(1)(ii) of the
Schedule TO). |
|
|
(a)(1)(iii) |
Notice of
Guaranteed Delivery (incorporated by reference to Exhibit (a)(1)(iii)
of the Schedule TO). |
|
|
(a)(1)(iv) |
Letter
to Brokers, Dealers, Banks, Trust Companies and other Nominees
(incorporated by reference to Exhibit (a)(1)(iv) of the Schedule
TO). |
|
|
(a)(1)(v) |
Letter to Clients for
use by Brokers, Dealers, Banks, Trust Companies and other Nominees
(incorporated by reference to Exhibit (a)(1)(v) of the Schedule
TO). |
|
|
(a)(1)(vi) |
Guidelines for
Certification of Taxpayer Identification Number on Substitute Form W-9
(incorporated by reference to Exhibit (a)(1)(vi) of the Schedule
TO). |
|
|
(a)(1)(vii) |
Summary Advertisement
published February 16, 2005 (incorporated by reference to Exhibit
(a)(1)(vii) of the Schedule TO). |
|
|
(a)(1)(viii) |
Text of Joint Press Release
issued by Danisco A/S and Genencor International, Inc. on January 27,
2005 (incorporated by reference to Exhibit 99.1 to the Schedule TO
filed by Danisco A/S on January 27, 2005). |
|
|
(a)(2) |
Schedule 14d-9 Solicitation or
Recommendation Materials (incorporated by reference to Schedule 14d-9
filed by Genencor International, Inc. on February 15, 2005). |
|
|
(a)(5)(i) |
Complaint of Ronald Zappolla
against Genencor International, Inc., et al., Civil Action No. 1052-N,
filed in the Court of Chancery of the State of Delaware on January 27,
2005 (incorporated by reference to Exhibit (a)(5)(i) of the Schedule
TO). |
|
|
(a)(5)(ii) |
Complaint of Mirfred
Partners LLC against Genencor International, Inc., et al., Civil Action
No. 1053-N, filed in the Court of Chancery of the State of Delaware on
January 27, 2005 (incorporated by reference to Exhibit (a)(5)(ii) of
the Schedule TO). |
|
|
(a)(5)(iii) |
Complaint of Dennis Rice
against Genencor International, Inc., et al., Civil Action No. 105CV
034734, filed in Superior Court of the State of California, County of
Santa Clara on January 27, 2005 (incorporated by reference to Exhibit
(a)(5)(iii) of the Schedule TO). |
1
|
|
(a)(5)(iv) |
Complaint
of Walter Slobodan against Genencor International, Inc., et al., Civil
Action No. 1072-N, filed in the Court of Chancery of the State of
Delaware on February 4, 2005 (incorporated by reference to Exhibit
(a)(5)(iv) of the Schedule TO). |
|
|
(a)(5)(v) |
Complaint of John Baker against
Genencor International, Inc. et al. Civil Action No. 105CV
035309, filed in the Superior Court of the State of California, County
of Santa Clara on February 8, 2005 (incorporated by reference to
Exhibit (a)(5)(v) of the Schedule TO). |
|
|
(a)(5)(vi)†* |
Presentation of Lehman
Brothers to the Board of Directors of Genencor International, Inc.,
dated June 3, 2004. |
|
|
(a)(5)(vii)†* |
Presentation of
Lehman Brothers to the Board of Directors of Genencor International,
Inc., dated September 8, 2004. |
|
|
(a)(5)(viii)* |
Memo from Genencor
International, Inc. to Lehman Brothers dated March 18, 2004. |
|
|
(a)(5)(ix) |
Certain projected financial
data from the May 2004 Confidential Descriptive
Memorandum. |
|
|
(b) |
Commitment Letter,
dated February 4, 2005, from Danske Bank to Danisco A/S (incorporated
by reference to Exhibit 99.8 to Schedule 13D filed by Danisco A/S on
February 7, 2005). |
|
|
(c)(1)* |
Presentation of UBS Securities LLC
to the Special Committee of the Board of Directors of Genencor
International, Inc., dated December 22, 2004. |
|
|
(c)(2)*
|
Presentation of UBS Securities LLC to the Special
Committee of the Board of Directors of Genencor International, Inc.,
dated January 25, 2005. |
|
|
(c)(3)* |
Presentation of UBS Securities LLC
to the Special Committee of the Board of Directors of Genencor
International, Inc., dated January 26, 2005. |
|
|
(c)(4) |
Opinion of UBS Securities LLC,
dated January 26, 2005 (incorporated by reference to Annex B of
Schedule 14D-9 filed by Genencor International, Inc. on February 15,
2005). |
|
|
(d)(1) |
Acquisition Agreement,
dated January 27, 2005, among Danisco A/S, DH Subsidiary Inc. and
Genencor International, Inc. (incorporated by reference to Exhibit 2.1
to Genencor International, Inc.'s current report on Form 8-K
dated January 27, 2005). |
|
|
(d)(2) |
Stock
Purchase Agreement, dated January 27, 2005, among Danisco A/S, DH
Subsidiary Inc., Eastman Chemical Company and Eastman Chemical Company
Investments, Inc. (incorporated by reference to Exhibit (d)(2) to the
Schedule TO). |
|
|
(d)(3)(i) |
Stockholder
Agreement, dated July 25, 2000, among Danisco A/S, Eastman Chemical
Company and Genencor International, Inc. (incorporated by reference to
Exhibit 10.5 to Amendment No. 4 to Genencor International, Inc.'s
registration statement on Form S-1 (Registration No. 333-36452) filed
on July 26, 2000). |
|
|
(d)(3)(ii) |
First
Amendment to Stockholder Agreement, dated February 16, 2001, among
Danisco A/S, Eastman Chemical Company and Genencor International, Inc.
(incorporated by reference to Exhibit 10.2 to Genencor International,
Inc.'s annual report on Form 10-K for the year ended December 31,
2002). |
|
|
(d)(3)(iii) |
Second Amendment to
Stockholder Agreement, dated November 15, 2002, among Danisco A/S,
Eastman Chemical Company and Genencor International, Inc. (incorporated
by reference to Exhibit 10.3 to Genencor International, Inc.'s
annual report on Form 10-K for the year ended December 31, 2002). |
|
|
(d)(3)(iv) |
Third Amendment to Stockholder
Agreement, dated April 2, 2003, among Danisco, Eastman and the Issuer
(incorporated by reference to Exhibit 10.4 to the Issuer's annual
report on Form 10-K for the year ended December 31, 2003). |
2
|
|
(d)(3)(v) |
Fourth
Amendment to Stockholder Agreement, dated January 27, 2005, among
Danisco A/S, Eastman Chemical Company and Genencor International, Inc.
(incorporated by reference to Exhibit 10.1 to Genencor International,
Inc.'s current report on Form 8-K dated January 27, 2005). |
|
|
(f) |
Section 262 of the Delaware General
Corporation Law (incorporated by reference to Annex C in the Offer to
Purchase filed as Exhibit (a)(1)(i)) to the Schedule TO. |
|
|
(g) |
None. |
|
|
† |
Confidential treatment has been requested
with respect to certain portions of this exhibit. Omitted portions have
been filed separately with the SEC. |
|
|
* |
Previously
filed. |
3
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true,
complete and correct.
|
GENENCOR INTERNATIONAL,
INC. |
|
|
|
|
By: |
/s/ Jean-Jacques
Bienaimé
Name: Jean-Jacques Bienaimé
Title: Chairman, Chief Executive Officer and
President |
Dated: February 22,
2005
4